Related references
Note: Only part of the references are listed.Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
Stephan B. Dreyer et al.
GASTROENTEROLOGY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The Gene Ontology resource: enriching a GOld mine
Seth Carbon et al.
NUCLEIC ACIDS RESEARCH (2021)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Brian A. Lanman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discoidin Domain Receptor 1 (DDR1) Is Necessary for Tissue Homeostasis in Pancreatic Injury and Pathogenesis of Pancreatic Ductal Adenocarcinoma
Jeanine M. Ruggeri et al.
AMERICAN JOURNAL OF PATHOLOGY (2020)
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Clint A. Stalnecker et al.
SCIENCE SIGNALING (2020)
Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics
Naiara Santana-Codina et al.
CELL REPORTS (2020)
JAK-STAT Signalling Pathway in Cancer
Andrew J. Brooks et al.
CANCERS (2020)
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
Irem Ozkan-Dagliyan et al.
CELL REPORTS (2020)
Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases
Justin F. Creeden et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Ras-Mediated Activation of the Raf Family K nases
Elizabeth M. Terrell et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)
KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
Kevin Lou et al.
SCIENCE SIGNALING (2019)
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review
Jehanya Jegatheeswaran et al.
IMMUNOTHERAPY (2019)
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
Kyle C. Cuneo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Andrew J. Aguirre et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Herve Tiriac et al.
CANCER DISCOVERY (2018)
Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer
Kyla A.L. Collins et al.
Oncotarget (2018)
Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth
Linas J. Krulikas et al.
SLAS DISCOVERY (2018)
Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer
Nagaraj S. Nagathihalli et al.
CANCER RESEARCH (2018)
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Angelina V. Vaseva et al.
CANCER CELL (2018)
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
Arun M. Unni et al.
ELIFE (2018)
In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma
C. Ambrogio et al.
ONCOGENE (2017)
Emerging protein kinase inhibitors for treating pancreatic cancer
Junji Furuse et al.
EXPERT OPINION ON EMERGING DRUGS (2017)
A compendium of ERK targets
Evrim B. Uenal et al.
FEBS LETTERS (2017)
Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells
Ho-June Lee et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma
Kristina Y. Aguilera et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability
Jeran K. Stratford et al.
PLOS ONE (2017)
Survival of pancreatic cancer cells lacking KRAS function
Mandar Deepak Muzumdar et al.
NATURE COMMUNICATIONS (2017)
Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers
Josephine Hai et al.
CLINICAL CANCER RESEARCH (2017)
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Mariaelena Pierobon et al.
CLINICAL CANCER RESEARCH (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Stephan B. Dreyer et al.
CLINICAL CANCER RESEARCH (2017)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K. Hayes et al.
CANCER CELL (2016)
Targeting NEK2 as a promising therapeutic approach for cancer treatment
Yanfen Fang et al.
CELL CYCLE (2016)
Cytokinetic effects of Wee1 disruption in pancreatic cancer
Qing Chang et al.
CELL CYCLE (2016)
Negative feedback regulation of the ERK1/2 MAPK pathway
David Lake et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Mapping the Pathways of Resistance to Targeted Therapies
Kris C. Wood
CANCER RESEARCH (2015)
Organoid Models of Human and Mouse Ductal Pancreatic Cancer
Sylvia F. Boj et al.
CELL (2015)
Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment
Todd VanArsdale et al.
CLINICAL CANCER RESEARCH (2015)
Durability of Kinase-Directed Therapies-A Network Perspective on Response and Resistance
Brion W. Murray et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine
Elisa Baldelli et al.
PROTEOMICS CLINICAL APPLICATIONS (2015)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz et al.
NATURE COMMUNICATIONS (2015)
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
Arun M. Unni et al.
ELIFE (2015)
Identification of Weel as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
E. Weisberg et al.
LEUKEMIA (2015)
Analysis of drug combinations: current methodological landscape
Julie Foucquier et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response
Elda Grabocka et al.
CANCER CELL (2014)
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
Colin A. Martz et al.
SCIENCE SIGNALING (2014)
STAT3 Phosphorylation at Tyrosine 705 and Serine 727 Differentially Regulates Mouse ESC Fates
Guanyi Huang et al.
STEM CELLS (2014)
Discovery and Optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)-ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (DDR1) Inhibitors
Mingshan Gao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
Sarat Chandarlapaty
CANCER DISCOVERY (2012)
Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation
Livio Trusolino et al.
CANCER DISCOVERY (2012)
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
Eric A. Collisson et al.
CANCER DISCOVERY (2012)
STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis
Ryan B. Corcoran et al.
CANCER RESEARCH (2011)
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells
Yun Dai et al.
BLOOD (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Serine phosphorylation of STATs
T Decker et al.
ONCOGENE (2000)
Share Paper
